Don't wait for an emergency to get the latest emergency medicine news
NewswiseFind the latest research and features on emergency medicine in the Emergency Medicine channel on Newswise.
Find the latest research and features on emergency medicine in the Emergency Medicine channel on Newswise.
Little is known about the factors associated with first responder drug and alcohol use during the pandemic. A new study shows that nearly 40 percent of law enforcement personnel, firefighters and emergency medical service providers reported using substances to relieve emotional discomfort during COVID-19.
Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.
By taking advantage of mechanisms that allow cancer cells to evade immune attack, UT Southwestern Medical Center researchers have developed a new strategy in animal models that has potential for treating ulcerative colitis.
Researchers have developed a platform that combines automated experiments with AI to predict how chemicals will react with one another, which could accelerate the design process for new drugs.
Hackensack Meridian Neuroscience Institute at Jersey Shore University Medical Center’s ALS Center is the first ALS care provider in the United States to offer patients a new interventional clinical study.
Antibiotic overuse can lead to antibiotic resistance, a global health problem. But UNC School of Medicine scientists with Duke School of Medicine colleagues have documented another culprit in clinical antibiotic failure: bacterial persister cells.
An increased concentration of the hormone leptin in fat cells is believed to be responsible for weight gain associated with antipsychotic drugs, according to research led by UT Southwestern Medical Center. The study, published in Science Translational Medicine, used a mouse model to uncover the underlying mechanisms of unwanted metabolic side effects and to test an antibody that might reduce them.
Researchers have found a gene that links deafness to cell death in the inner ear in humans – creating new opportunities for averting hearing loss.
Cell replication in our bodies is triggered by a cascade of molecular signals transmitted between proteins. Compounds that block these signals show potential as cancer drugs. Recently, scientists uncovered the molecular mechanisms that underlie a step in the signal-transmission pathway that requires three proteins to link up. This points the way to new targets for drugs that fight certain types of cancer.
In cooperation with research partners in Germany and France, the infectious disease specialist Dr Jan Rybniker and his team at University Hospital Cologne and the University of Cologne’s Faculty of Medicine have identified new, antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans.
Find the latest research and features on fertility in the Fertility News Source on Newswise.
Doctors at the UNC School of Medicine and Cincinnati Children’s collaborate to develop an innovative, patient-initiated online platform designed to remove the penicillin allergy label from misdiagnosed pediatric patients.
A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.
New research from Sylvester Comprehensive Cancer Center indicates that providing prophylactic treatment before immunotherapy can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. Study appears Jan. 4, 2024, in Blood Cancer Discovery.
A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease.
A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a new study shows.
In an NIH-funded study, UC Davis pulmonology researchers are exploring whether delivering statins by inhalation can lead to better outcomes for people with asthma.
Molecular diagnostics is a powerful branch of laboratory medicine that examines the fundamental genetic and biochemical components of life to provide invaluable insights into health and disease.
Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score. The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2]. Studies have shown that drugs have an increased likelihood of success in clinical trials when the genes they target have been demonstrated to have genetic support. The new tool integrates multiple lines of genetic evidence to prioritize these drug targets.
حدد الباحثون والمتعاونون في مايو كلينك بروتينًا تفرزه الخلايا المناعية والذي قد يقوم بدورٍ رئيسيٍ في ظهور مرضالتصلُّب الجانبي الضموري، المعروف أيضًا باسم مرض لو غيريغ. ووجد الفريق أيضًا أن العلاج التعديلي المناعي الذي يقوم بعملية إِحْصار للبروتين يمكنه استعادة الوظيفة الحركية في النماذج قبل السريرية. وتشير النتائج إلى أن البروتين، المعروف باسم أ5 إنتغرين (الذي يُنطق ألفا 5 إنتغرين)، هو مستهدف علاجي محتمل لعلاج مرض التصلُّب الجانبي الضموري.
Los investigadores y colaboradores de Mayo Clinic han identificado una proteína expresada en células inmunitarias que podría desempeñar un rol clave en el desarrollo de la esclerosis lateral amiotrófica (ELA), también conocida como enfermedad de Lou Gehrig. El equipo también descubrió que un tratamiento inmunomodulatorio que bloquea la proteína era capaz de restaurar la función motriz en modelos preclínicos. Los hallazgos indican que la proteína, conocida como integrina α5 (pronunciado integrina alfa 5), es un posible blanco terapéutico para la ELA.
Pesquisadores e colaboradores da Mayo Clinic identificaram uma proteína que é expressa por células imunológicas que pode desempenhar uma função importante no desenvolvimento daesclerose lateral amiotrófica (ELA), também conhecida como doença de Lou Gehrig. A equipe também descobriu que um tratamento imunomodulador que bloqueia a proteína conseguiu restaurar a função motora em modelos pré-clínicos. As descobertas sugerem que a proteína, conhecida como integrina α5 (pronunciada como integrina alfa 5), é um possível alvo terapêutico para ELA.
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway. Their findings, detailed in the January 2 online issue of Nature Communications https://doi.org/10.1038/s41467-023-44601-4, show that a brain protein known as the TAAR1 receptor, a drug target known to regulate dopamine signaling in key reward pathways in the brain, differs significantly in humans compared to the preclinical rodent models on which drugs are typically tested. The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.
The Radiopharmaceutical Therapy and Dosimetry Lab at Johns Hopkins Medicine, headed by George Sgouros, Ph.D., has been awarded a $15 million grant, to be dispersed over the next five years, from the National Cancer Institute at the National Institutes of Health.
Patient-specific mutation-engineered mouse reveals how sensory neurons may trigger some allergy conditions but block others, suggesting more precise design of JAK inhibitors is necessary.
With the rise in machine learning applications and artificial intelligence, it's no wonder that more and more scientists and researchers are turning to supercomputers. Supercomputers are commonly used for making predictions with advanced modeling and simulations. This can be applied to climate research, weather forecasting, genomic sequencing, space exploration, aviation engineering and more.
Alzheimer’s disease (AD) is associated with damaging protein aggregates in the brain, with β-amyloid (Aβ) aggregates called plaques being the key pathology. Entresto (sacubitril/valsartan) is a combined neprilysin inhibitor and angiotensin receptor blocker, approved for the treatment of heart failure.
The authors of this study verified that Forsythiae Fructus and Forsythrin A and phillyrin has a therapeutic effect on CINV, and it also provides a reference treatment for the management of CINV.
Results from a phase II clinical trial indicate that psilocybin, a hallucinogenic chemical found in certain mushrooms of the genus Psiloybe, may benefit individuals with cancer and major depression.
Nabsolute Co., Ltd., a startup from the Faculty of Pharmaceutical Science, Chulalongkorn University, developer of Hy-N, an innovative biopolymer delivery system that improves the efficiency of cosmeceuticals, medicines, and vaccines, received the 2023 National Innovation Award in the economic category as a small and micro-enterprise from the National Innovation Agency (NIA).
Singleton is the lead author of a study that shows how a combination of two new substances effectively kills methicillin-resistant Staphylococcus aureus (MRSA).
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, today announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc. (Janssen), a Johnson & Johnson company.
More than one-eighth of the randomized trials of cancer drugs seeking regulatory approval in China in recent years used inappropriate controls to test the effectiveness and safety of the drugs, according to a new study published December 12th in the open access journal PLOS Medicine by Professor Xiaodong Guan of Peking University, China, and colleagues.
Lower levels of vitamin D found in inflammatory bowel disease (IBD) patients are linked to inflammation, potentially playing a role in the disease's development, findings from a cross-sectional observational study published in Medicine® show.
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin — the go-to primary drug for glucose management — to control their blood sugar levels. But adherence to these second-line drugs can be hit or miss, reports a new Northwestern Medicine study.
Tuberculosis (TB) is a prevalent infectious disease that affects millions of people each year. It was previously the leading cause of death from a single pathogen before the COVID-19 pandemic. Detecting TB early is challenging because the bacterium Mycobacterium tuberculosis (Mtb) can hide in human macrophages, which are part of the immune system
Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer’s disease (AD) therapy.
Antibodies (immunoglobulins) are Y-shaped proteins that recognize and neutralize specific pathogens. Their ability to target specific molecules or cells has made them promising candidates for future drug development.
Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found to be so effective. Importantly, the data also reveals how anti-obesity drugs like Ozempic, actually work, which to date have been a mystery.